selegiline has been researched along with propargylamine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Barber, QR; Bergh, JJ; Joubert, J; Malan, SF; Petzer, JP; Zindo, FT | 1 |
| Boulton, AA; Davis, BA; Fang, J; Yu, PH | 1 |
| Carrillo, MC; Kitani, K; Maruyama, W; Naoi, M; Yamamoto, T; Youdim, M | 1 |
| Carrillo, MC; Ivy, GO; Kanai, S; Kitani, K; Maruyama, W; Minami, C | 1 |
| Carrillo, MC; Ivy, GO; Kanai, S; Kitani, K; Minami, C; Yamamoto, T | 1 |
| Chalmers-Redman, R; Tatton, N; Tatton, W | 1 |
| Jenner, P | 1 |
| Olanow, CW | 1 |
| Kálmán, M; Pálfi, M; Szökó, E | 1 |
| Akao, Y; Maruyama, W; Naoi, M; Shamoto-Nagai, M; Yamaoka, Y; Yi, H | 1 |
| Legoabe, LJ; Meiring, L; Petzer, A; Petzer, JP | 1 |
4 review(s) available for selegiline and propargylamine
| Article | Year |
|---|---|
Pharmacological interventions in aging and age-associated disorders: potentials of propargylamines for human use.
Topics: Aging; Animals; Catalase; Free Radical Scavengers; Humans; Life Expectancy; Neuroprotective Agents; Pargyline; Propylamines; Selegiline; Superoxide Dismutase | 2002 |
Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Survival; Glyceraldehyde-3-Phosphate Dehydrogenases; HSP70 Heat-Shock Proteins; Humans; Monoamine Oxidase; Neurons; Neuroprotective Agents; Pargyline; Parkinson Disease; Propylamines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Selegiline; Superoxide Dismutase | 2003 |
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Haplorhini; Humans; Inactivation, Metabolic; Indans; Mice; Mice, Transgenic; Models, Neurological; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Oxepins; Oxidative Stress; Pargyline; Parkinson Disease; Propylamines; Selegiline | 2004 |
[Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].
Topics: Animals; Antioxidants; Antiparkinson Agents; Apoptosis; Dopamine; Drug Synergism; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Mitochondria; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Pargyline; Phosphotransferases; Poly(ADP-ribose) Polymerases; Propylamines; Selegiline | 2006 |
7 other study(ies) available for selegiline and propargylamine
| Article | Year |
|---|---|
Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
Topics: Acetylene; Apoptosis; Calcium Channel Blockers; Calcium Channels, L-Type; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Pargyline; Propylamines; Protein Conformation; Receptors, N-Methyl-D-Aspartate | 2014 |
Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus.
Topics: Animals; Benzylamines; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Hippocampus; Male; Mice; Monoamine Oxidase Inhibitors; Neurons; Neurotransmitter Uptake Inhibitors; Norepinephrine; Pargyline; Phenelzine; Propylamines; Selegiline; Time Factors | 1994 |
Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.
Topics: Animals; Apoptosis; Humans; Indans; Molecular Structure; Molsidomine; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Pargyline; Propylamines; Rats; Rats, Inbred F344; Selegiline; Tumor Cells, Cultured | 2000 |
Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)deprenyl.
Topics: Age Factors; Animals; Brain; Catalase; Dogs; Dopamine; Dose-Response Relationship, Drug; Longevity; Mice; Mice, Inbred Strains; Pargyline; Propylamines; Rats; Rats, Inbred Strains; Selegiline; Sex Factors; Superoxide Dismutase | 2000 |
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Pargyline; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians'; Propylamines; Selegiline; Treatment Outcome | 2006 |
Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.
Topics: Alkynes; Cell Death; Cell Line, Tumor; Energy Metabolism; Genetic Markers; Glial Cell Line-Derived Neurotrophic Factor; Humans; Indans; Membrane Potentials; Mitochondria; Neuroblastoma; Neuroprotective Agents; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pargyline; Parkinson Disease; Propylamines; Proto-Oncogene Proteins c-bcl-2; Selegiline | 2007 |
The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Propylamines; Selegiline; Tetrahydronaphthalenes; Tyramine | 2022 |